Kinase inhibitors inhibit downstream signaling pathways and thereby interfere with survival, activation, proliferation, and differentiation of normal and malignant cells. Kinase inhibitors are increasingly used to treat hematological malignancies, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL).